🔴 Nuvation Bio is trading 6% down in pre-market after EPS loss misses estimates despite revenue beat

Nuvation Bio is trading 6.17% down now at $5.98 in pre-market after its August 6, 2026 second-quarter earnings release showed an EPS loss of $0.18, worse than expected.

• Revenue was $31.7 million, above the $26.5 million consensus estimate.
• Strong IBTROZI sales were not enough to offset the earnings miss.
• The company scheduled its results call for 8:00 a.m. ET. [Earnings Report ID: 6a7473fceb68efc301522b02]